We work in low- and middle-income countries to expand access to high-quality chemotherapy, radiotherapy, surgery, and pain relief, as well as getting patients diagnosed and started on treatment earlier.
Explore our current global cancer treatment programs and initiatives on this page.
We work with the Clinton Health Access Initiative, through our Allied Against Cancer alliance, to engage pharmaceutical companies to provide world-class medications at affordable prices to treatment centers across sub-Saharan Africa. At the same time, Allied Against Cancer works with those who purchase medications to accurately plan and budget for their procurement, based on best-practice guidelines. The current participating pharmaceutical companies are Biocon Biologics, Novartis, Pfizer, and Viatris.
ChemoSafe is a comprehensive approach to promote the safe handling and administration of chemotherapy and quality service provision to patients in Sub-Saharan Africa. The program encompasses the lifecycle of chemotherapy delivery, including logistics, compounding, administration (including diagnostics and side effect management), and disposal. It engages all healthcare and facility workers with the potential for interaction with chemotherapy, such as physicians, pharmacists, nurses, students and trainees, cleaners, and laundry workers.
The African Cancer Coalition is a growing consortium of oncology experts in Africa working with the American Cancer Society, National Comprehensive Cancer Network (NCCN), the Clinton Health Access initiative to develop the NCCN Harmonized Guidelines for Sub-Saharan Africa. Coalition experts work with clinical professionals at NCCN member Institutions to outline approaches to managing cancer to achieve the highest standard of care with available resources. These Guidelines represent both the optimal care that these countries aspire to provide and pragmatic approaches that provide effective treatment options for resource-constrained settings.
The Treat the Pain program is designed to improve access to essential pain medicines. More than 3.2 billion people worldwide lack access to adequate pain relief even though morphine, the most effective treatment for severe pain, is safe, effective, plentiful, inexpensive, and easy-to-use. The program provides technical support to improve patient access to opioid analgesics, with a focus on low and middle-income countries with high unmet need for pain relief.